Would you consider de-escalating treatment to endocrine therapy alone in a patient with prolonged NED on CDK 4/6 inhibitor + endocrine therapy?
Patient is on fulvestrant+CDK 4/6 inhibitor and with NED for 5 years. In which cases would you consider stopping CDK 4/6 inhibitor?
Answer from: Medical Oncologist at Academic Institution
Be good to know more specifics about her breast cancer history, whether this is administered as a first line in an endocrine sensitive setting versus not. If her history is in line with endocrine sensitivity, I think it would be reasonable to de-escalate her treatment to endocrine therapy alone and ...
Sign in or Register to read more